Author

D. L. Tyrrell

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cell Biology· 2 Biochemistry· 1 Biophysics· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Organism:human· 3 Research Focus:cell type annotation· 2 Research Focus:drug response / drug discovery· 2 Research Focus:host-pathogen & immune response· 2 Assay:proteomics· 2 Assay:bulk RNA-seq· 1 Research Focus:development & morphogenesis· 1

Frequent Co-Authors

E. Arutyunova· 3 shared M. J. Lemieux· 3 shared M. Joyce· 3 shared C. Fischer· 2 shared H. S. Young· 2 shared J. C. Vederas· 2 shared J. Shields· 2 shared M. B. Khan· 2 shared

Activity by Year

2017-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersMicrobiology

E. Arutyunova

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

SARS-COV-2 Recombinant Receptor-Binding-Domain (RBD) Induces Neutralising Antibodies Against Variant Strains of SARS-CoV-2 and SARS-CoV-1

J. L. M. Law, M. Logan, M. Joyce, A. Landi, D. Hockman, K. Crawford, J. Johnson, G. LaChance, H. Saffran, J. Shields, E. Hobart, R. Brassard, E. Arutyunova, K. Pabbaraju, M. Croxen, , M. Houghton

This study shows that recombinant SARS-CoV-2 RBD induces neutralizing antibodies against variant strains and SARS-CoV-1, suggesting its potential as a vaccine candidate or booster.

bioRxiv · May 10, 2021Microbiology

N-Terminal finger stabilizes the reversible feline drug GC376 in SARS-CoV-2 Mpro

E. Arutyunova, M. B. Khan, C. Fischer, J. Lu, T. Lamer, W. Vuong, M. J. van Belkum, R. T. McKay, D. L. Tyrrell, J. C. Vederas, H. S. Young, M. J. Lemieux

This study characterizes the reversible inhibition of SARS-CoV-2 and SARS-CoV Mpro by GC376, showing nanomolar Ki values and domain swapping in the drug-bound structures.

bioRxiv · Feb 16, 2021Biophysics

Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication

W. Vuong, M. B. Khan, C. Fischer, E. Arutyunova, T. Lamer, J. Shields, H. A. Saffran, R. T. McKay, M. J. van Belkum, M. Joyce, H. S. Young, D. L. Tyrrell, J. C. Vederas, M. J. Lemieux

This paper shows that feline coronavirus drugs inhibit SARS-CoV-2 main protease and block virus replication in cell culture with low toxicity.

bioRxiv · May 3, 2020Biochemistry

In vitro hepatitis C virus infection and hepatic choline metabolism

K. Gobeil Odai, C. O'Dwyer, R. Steenbergen, T. A. Shaw, T. M. Renner, P. Ghorbani, M. Rezaaifar, S. Han, M.-A. Langlois, A. M. Crawley, R. S. Russell, J. P. Pezacki, D. L. Tyrrell, M. D. Fullerton

This study investigates how hepatitis C virus (HCV) infection affects choline metabolism in liver cells, showing that choline transport and metabolism are modulated during early infection, with varying effects depending on culture conditions.

Viruses · Jan 16, 2020Peer-reviewedCell Biology

Induction of differentiation and metabolic reprogramming in human hepatoma cells by adult human serum

R. H. Steenbergen, M. Oti, R. ter Horst, W. Tat, C. Neufeldt, A. Belovodskiy, T. T. Chua, W. J. Cho, M. Joyce, B. E. Dutilh, D. L. Tyrrell

This study shows that culturing human hepatoma cells in adult human serum restores liver-like morphology, metabolism, and organ-specific functions, suggesting that FBS may suppress these features.

bioRxiv · Aug 25, 2017Cell Biology